Pontifax

Lutris Pharma is an Israel-based biopharmaceutical company focused on improving anti-cancer therapy. It develops drugs to enhance treatment effectiveness, including a proprietary topical B-Raf inhibitor LUT014 that enables administration of epidermal growth factor receptor inhibitors without the cutaneous side effects that typically interrupt therapy. Founded in 2015 and based in Tel Aviv-Yafo, Lutris Pharma aims to improve treatment continuity and patient quality of life for those treated with EGFR inhibitors.

Indapta Therapeutics is a biotechnology company focused on developing an off-the-shelf, non-engineered NK (natural killer) cell therapy platform for treating blood and solid tumor cancers. The company aims to enhance the immune response and improve antibody therapy cytotoxicity.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

LB Pharmaceuticals Inc is a New York-based life sciences company focused on the discovery and development of drugs for central nervous system disorders. Established in 2015, the company is dedicated to commercializing novel and improved versions of well-established CNS treatments that have been successfully utilized abroad but have not been developed or marketed in the United States. LB Pharmaceuticals aims to create intellectual property around these advanced treatments, with its lead asset being LB-102, a patented version of amisulpride, widely recognized for its effectiveness in treating schizophrenia. By employing a pro-drug approach that alters amisulpride's chemical structure, the company seeks to enhance the drug's efficacy and safety, thereby providing improved treatment options for patients who do not respond adequately to existing therapies.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

ARMGO Pharma is a biopharmaceutical company focused on developing small-molecule therapeutics to treat debilitating cardiac, skeletal muscle, and neurological disorders. It develops Rycals, calcium release channel stabilizers that act on the ryanodine receptor/calcium release channel on the sarcoplasmic/endoplasmic reticulum to address chronic heart failure, arrhythmias, muscle disorders, cognitive disorders, and related conditions. The company was founded in 2004 and is based in Tarrytown, New York, with an additional office in New York, New York.

Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. It specializes in developing and manufacturing therapies specifically for rare eye diseases. The company is particularly focused on addressing Stargardt's disease, a juvenile retinal degeneration condition for which there are currently no available treatments. By concentrating on these rare diseases, Stargazer Pharmaceuticals aims to provide healthcare professionals with innovative therapeutic options for patients suffering from such conditions. The company is currently operating in stealth mode as it advances its research and development efforts.

Opiant Pharmaceuticals, a specialty pharmaceutical company based in Santa Monica, California, focuses on developing medicines to treat addictions and drug overdoses. Founded in 2005, the company has created NARCAN nasal spray, a widely recognized treatment for reversing opioid overdoses. Opiant's pipeline includes potential treatments for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company leverages intranasal and injectable delivery technologies to address these critical health issues.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Saniona is a pharmaceutical company focused on discovering and developing medicines that modulate ion channels to treat central nervous system disorders, autoimmune diseases, metabolic diseases, and pain. It operates a technology platform that enables investigation of ion channel targets, including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels, to create selective modulators. Its product pipeline includes Tesomet, SAN711, SAN903, and SAN2219; Tesomet has advanced to mid-stage trials for rare eating disorders, SAN711 completed a Phase 1 trial for neuropathic pain, SAN903 is positioned to enter Phase 1 trials for inflammatory and fibrotic disorders, and SAN2219 is in development. Saniona operates in the United States, Sweden, Germany, Denmark, and the United Kingdom.

ProQR Therapeutics is a biopharmaceutical company focused on developing RNA-based therapies for patients with severe genetic rare diseases. Its primary focus includes Leber's congenital amaurosis type 10, dystrophic epidermolysis bullosa, and other inherited retinal disorders.

Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Founded in 2012 and based in Rehovot, Israel, Raziel Therapeutics develops RZL-012, a novel synthetic small molecule for treating obesity. Its drug is injected into fat tissue, causing fat cell death at the injection site and resulting in long-lasting reduction of fat volume.

Adicet Bio is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer treatment. Its pipeline includes ADI-001, targeting CD20 for autoimmune diseases and B-cell lymphomas, and ADI-270, targeting renal cell carcinoma.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

89bio, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, established in 2018. The company is dedicated to developing and commercializing innovative therapies for liver and cardio-metabolic diseases. Its primary product candidate, pegozafermin, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) that is currently being advanced through clinical trials for the treatment of nonalcoholic steatohepatitis (NASH). 89bio believes that pegozafermin has the potential to effectively address key liver pathologies, including steatosis and fibrosis, as well as the underlying metabolic dysregulation associated with NASH. In addition, the company aims to broaden the application of pegozafermin to include the treatment of severe hypertriglyceridemia.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents specifically designed to combat multidrug-resistant (MDR) Gram-negative infections. Founded in 2014, the company employs its innovative drug discovery platform, PasNas, to identify pathogen-specific antibacterial properties of various molecules. This platform not only promotes compounds effective against MDR strains but also emphasizes the importance of incorporating favorable pharmacokinetic and toxicological characteristics early in the development process. By focusing on first-in-class drugs and leveraging new mechanisms of action, ABAC Therapeutics aims to provide scalable and effective therapeutic alternatives for patients afflicted by antibiotic-resistant bacterial pathogens, addressing a critical need in modern medicine. As of November 2019, ABAC Therapeutics operates as a subsidiary of Tibidabo Ventures.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of targeted therapeutics for cancer and rare diseases. Founded in 1993 and headquartered in Burlington, Massachusetts, the company employs its ArQule Kinase Inhibitor Platform to design and develop novel small molecule drugs. ArQule's pipeline includes several investigational therapies, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase for B-cell malignancies; miransertib, an AKT inhibitor for advanced endometrial cancer; and ARQ 75, also targeting AKT in solid tumors. Additionally, Derazantinib is a multi-kinase inhibitor in clinical trials for intrahepatic cholangiocarcinoma. The company has established license agreements with Basilea Pharmaceutica and Roivant Sciences for its therapeutic candidates. As of January 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

LogicBio Therapeutics, Inc. is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly for pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology platform, LogicBio aims to integrate corrective genes into patients' genomes to achieve therapeutic effects. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a serious condition that manifests at birth. Additionally, LogicBio is advancing other product candidates, including LB-101 and LB-301, the latter developed in collaboration with Takeda Pharmaceutical Company to address Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors, enhancing the potential of its gene therapy approaches. Founded in 2014, LogicBio is headquartered in Lexington, Massachusetts.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Tisbury Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for primary open-angle glaucoma. Established in 2017 and located in Beverly, Massachusetts, the company is advancing its clinical candidate, R-801. This innovative treatment works by enhancing fluid flow through the trabecular meshwork, utilizing mechanisms such as redox catalysis and K+-ATP channel activation. The company’s objective is to effectively reduce intraocular pressure, thereby providing significant relief for patients suffering from glaucoma.

TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.

ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's product pipeline includes Onapristone, a type 1 anti-progestin hormone blocker currently undergoing Phase I/II clinical studies for various solid tumors, including breast and endometrial cancers in post-menopausal women and advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I studies for solid tumors and hematological malignancies, as well as AR-42, another oral therapy currently in Phase I investigator-initiated studies targeting hematological malignancies and solid tumors. The company has established collaboration agreements with several institutions, enhancing its research and development efforts.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, specializing in the development of orally delivered large molecule therapeutics, particularly peptides and therapeutic proteins. The company aims to address unmet medical needs in chronic conditions by offering a user-friendly oral drug delivery system. Its lead product candidates include EB612, an oral formulation of parathyroid hormone currently in Phase II clinical trials for hypoparathyroidism, and EB613, which is also in Phase II trials for osteoporosis and is being developed for non-union fractures. Entera Bio employs proprietary delivery technology that protects these large molecules in the gastrointestinal tract, enhancing their therapeutic potential. Founded in 2009, the company boasts a management team with over 50 years of combined experience in drug development, enabling efficient advancement of its innovative products.

TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.

Sweetch is a behavioral science company that utilizes artificial intelligence and emotional intelligence to provide digital therapeutic solutions. The company has developed a hyper-personalized engagement platform designed to enhance clinical outcomes for individuals with chronic conditions. This platform offers tailored recommendations that consider the right timing, tone, and real-world context, guiding patients throughout their health journey. By catering to the specific needs of patients, Sweetch enables pharmaceutical companies, device manufacturers, payers, and healthcare providers to establish continuous relationships and effectively engage with each individual at scale.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

Adicet Bio is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer treatment. Its pipeline includes ADI-001, targeting CD20 for autoimmune diseases and B-cell lymphomas, and ADI-270, targeting renal cell carcinoma.

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's product pipeline includes Onapristone, a type 1 anti-progestin hormone blocker currently undergoing Phase I/II clinical studies for various solid tumors, including breast and endometrial cancers in post-menopausal women and advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I studies for solid tumors and hematological malignancies, as well as AR-42, another oral therapy currently in Phase I investigator-initiated studies targeting hematological malignancies and solid tumors. The company has established collaboration agreements with several institutions, enhancing its research and development efforts.

Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's product pipeline includes Onapristone, a type 1 anti-progestin hormone blocker currently undergoing Phase I/II clinical studies for various solid tumors, including breast and endometrial cancers in post-menopausal women and advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I studies for solid tumors and hematological malignancies, as well as AR-42, another oral therapy currently in Phase I investigator-initiated studies targeting hematological malignancies and solid tumors. The company has established collaboration agreements with several institutions, enhancing its research and development efforts.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, focused on developing innovative therapies for specialty cancers and urologic diseases. The company is dedicated to transforming the standard of care in uro-oncology through its diverse pipeline of product candidates. Its lead products, including UGN-101 and UGN-102, aim to ablate tumors non-surgically and address various forms of non-muscle invasive urothelial cancer, such as low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. UroGen is also advancing UGN-201, an immunotherapy candidate targeting high-grade non-muscle invasive bladder cancer. Furthermore, the company's proprietary RTGel technology enhances drug delivery by enabling sustained release, improving therapeutic efficacy. UroGen has established licensing agreements with Allergan Pharmaceuticals for the development of RTGel-based products and with Agenus Inc. to commercialize treatments for urinary tract cancers. Founded in 2004, UroGen Pharma continues to innovate in the field of urology and oncology.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

cCAM Biotherapeutics Ltd. is a clinical-stage biotechnology company based in Misgav, Israel, focused on the discovery and development of innovative immunotherapies for cancer treatment. The company is developing CM-10, an immunomodulatory antibody designed to enhance the immune system's ability to target and attack tumors by binding to CEACAM1, a protein that cancer cells exploit to evade immune responses. cCAM's lead therapeutic candidate, CM-24, is a humanized anti-CEACAM1 monoclonal antibody aimed at treating advanced and recurrent cancers, including melanoma, non-small-cell lung cancer, bladder, gastric, colorectal, and ovarian cancers. Established in 2010, cCAM Biotherapeutics aims to provide effective treatment options for patients facing various malignancies.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, specializing in the development of innovative drugs that leverage the unique structural and electrical properties of biological membranes. Founded in 1996, Aposense focuses on creating molecular nano-motors capable of harnessing energy from intra-membrane electric fields to facilitate the delivery of genetic drugs, such as siRNA, into cells. The company has developed a platform technology known as Apo-Si, which supports targeted therapy and real-time clinical imaging of disease activity, particularly in oncology, cardiology, and neurology. Aposense is also advancing its proprietary drug candidate, ATT-11T, a conjugate designed to treat solid tumors by combining a molecular nano-motor with SN-38, the active component of irinotecan. With its commitment to transforming apoptosis targeting into practical applications, Aposense is at the forefront of integrating advanced therapeutic strategies into personalized patient care.

Applied Immune Technologies Ltd. is engaged in the development of therapeutic molecules aimed at treating cancer, viral, and autoimmune diseases. The company specializes in T-Cell Receptor-Like (TCRL) antibodies that target intracellular-derived peptides for both therapeutic and diagnostic purposes. These antibodies have applications in pathology, vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in various diseases. Established in 2006 and based in Haifa, Israel, Applied Immune Technologies was previously known as BioMimic Pharma. The company operates as a subsidiary of Adicet Bio, Inc.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, specializing in the development of innovative drugs that leverage the unique structural and electrical properties of biological membranes. Founded in 1996, Aposense focuses on creating molecular nano-motors capable of harnessing energy from intra-membrane electric fields to facilitate the delivery of genetic drugs, such as siRNA, into cells. The company has developed a platform technology known as Apo-Si, which supports targeted therapy and real-time clinical imaging of disease activity, particularly in oncology, cardiology, and neurology. Aposense is also advancing its proprietary drug candidate, ATT-11T, a conjugate designed to treat solid tumors by combining a molecular nano-motor with SN-38, the active component of irinotecan. With its commitment to transforming apoptosis targeting into practical applications, Aposense is at the forefront of integrating advanced therapeutic strategies into personalized patient care.